Eli Lilly and Company
1,124.21USD
+0.2999 (+0.03%)
Computing valuation metrics…
Valuation
P/E (TTM)
37.53x
P/E (Forward)
23.79x
EV/EBITDA
25.12x
EV/Revenue
13.15x
P/S (TTM)
12.58x
P/B
29.59x
FCF Yield
0.58%
Dividend Yield
0.62%
Gross Margin
83.40%
Operating Margin
54.22%
Net Margin
33.53%
Peer Comparison — Drug Manufacturers - General
| Company | Mkt Cap | P/E | EV/EBITDA | FCF Yield | Rev Growth | Div Yield |
|---|---|---|---|---|---|---|
| LLYEli Lilly and Company | $1.00T | 37.53x | 25.12x | 0.58% | 47.67% | 0.62% |
| JNJJohnson & Johnson | $643.64B | 31.02x | 19.41x | 2.62% | 6.60% | 1.99% |
Subject metrics from SEC filings where available; peer metrics from cached market data.
| $443.39B |
| 71.08x |
| 16.50x |
| 3.80% |
| 10.20% |
| 2.78% |
| MRKMerck & Co., Inc. | $363.98B | 118.02x | 14.31x | 4.17% | 5.10% | 2.29% |
| NVSNovartis AG | $261.31B | 20.77x | 13.12x | 4.55% | 0.80% | 3.44% |
| AMGNAmgen Inc. | $211.53B | 24.33x | 14.76x | 4.09% | 9.50% | 2.56% |
| GILDGilead Sciences, Inc. | $180.60B | — | 13.83x | 5.41% | 10.20% | 2.24% |
| PFEPfizer Inc. | $158.39B | 36.57x | 8.44x | 7.88% | 2.60% | 6.05% |
| BMYBristol-Myers Squibb Company | $131.57B | 14.19x | 8.75x | 6.17% | 5.70% | 3.90% |